Taro Semba

7PUBLICATIONS
82CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Mechanobiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 15, 2026
Preclinical Evaluation of Liposomal Eribulin (E7389-LF) in a Panel of Sarcoma Patient-Derived Xenograft Models.

|Jan 31, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.

Akihito Kawazoe, Noboru Yamamoto, Naotoshi Sugimoto

|Jan 05, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Makoto Nishio, Shuji Murakami, Hisato Kawakami

|Oct 10, 2023
Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities.

Ken Ito, Masayuki Yamaguchi, Taro Semba

|Jul 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Hanae Ida, Toshio Shimizu, Makoto Nishino

|Feb 02, 2023
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.

Kohei Shitara, Motohiro Hirao, Satoru Iwasa

Pageof 2

Frequent Collaborators

4 joint publications

Takao Takase

3 joint publications

Kan Yonemori

3 joint publications

Daiko Matsuoka

3 joint publications

Yohei Otake